Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease

REFERENCES

1. 1.↵
   2. Walker FO

   . Huntington's disease. Lancet 2007;369:218–28 doi:10.1016/S0140-6736(07)60111-1 pmid:17240289

   CrossRefPubMedWeb of Science
2. 2.↵
   2. McColgan P,
   3. Tabrizi SJ

   . Huntington's disease: a clinical review. Eur J Neurol 2018;25:24–34 doi:10.1111/ene.13413 pmid:28817209

   CrossRefPubMed
3. 3.↵
   2. Haller S,
   3. Xekardaki A,
   4. Delaloye C, et al

   . Combined analysis of grey matter voxel-based morphometry and white matter tract-based spatial statistics in late-life bipolar disorder. J Psychiatry Neurosci 2011;36:391–401 doi:10.1503/jpn.100140 pmid:21284917

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Weston PSJ,
   3. Simpson IJA,
   4. Ryan NS, et al

   . Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. Alzheimers Res Ther 2015;7:47 doi:10.1186/s13195-015-0132-3 pmid:26136857

   CrossRefPubMed
5. 5.↵
   2. Illán-Gala I,
   3. Montal V,
   4. Borrego-Écija S, et al

   ; Catalan Frontotemporal Dementia Initiative (CATFI) and the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI). Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain 2019;142:1121–33 doi:10.1093/brain/awz031 pmid:30906945

   CrossRefPubMed
6. 6.↵
   2. Martinez-Horta S,
   3. Perez-Perez J,
   4. van Duijn E, et al

   ; Spanish REGISTRY investigators of the European Huntington's Disease Network. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease. Parkinsonism Relat Disord 2016;25:58–64 doi:10.1016/j.parkreldis.2016.02.008 pmid:26898966

   CrossRefPubMed
7. 7.↵
   2. Tabrizi SJ,
   3. Langbehn DR,
   4. Leavitt BR, et al

   ; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801 doi:10.1016/S1474-4422(09)70170-X pmid:19646924

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Shoulson I,
   3. Fahn S

   . Huntington disease: clinical care and evaluation. Neurology 1979;29:1–3 doi:10.1212/WNL.29.1.1 pmid:154626

   FREE Full Text
9. 9.↵
   2. Penney JB Jr.,
   3. Vonsattel JP,
   4. MacDonald ME, et al

   . CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689–92 doi:10.1002/ana.410410521 pmid:9153534

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Langbehn DR,
    3. Hayden M,
    4. Paulsen JS

    ; PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010;153B:397–408 doi:10.1002/ajmg.b.30992 pmid:19548255

    CrossRefPubMed
11. 11.↵
    2. Terwindt PW,
    3. Hubers AA,
    4. Giltay EJ, et al

    . Screening for cognitive dysfunction in Huntington's disease with the clock drawing test. Int J Geriatr Psychiatry 2016;31:1013–20 doi:10.1002/gps.4412 pmid:26766850

    CrossRefPubMed
12. 12.↵
    2. Fischl B,
    3. Dale AM

    . Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000;97:11050–55 doi:10.1073/pnas.200033797 pmid:10984517

    Abstract/FREE Full Text
13. 13.↵
    2. Yendiki A,
    3. Panneck P,
    4. Srinivasan P, et al

    . Automated probabilistic reconstruction of white-matter pathways in health and disease using an atlas of the underlying anatomy. Front Neuroinform 2011;5:23 doi:10.3389/fninf.2011.00023 pmid:22016733

    CrossRefPubMed
14. 14.↵
    2. Niccolini F,
    3. Pagano G,
    4. Fusar-Poli P, et al

    . Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. J Neurol Neurosurg Psychiatry 2018;89:185–96 doi:10.1136/jnnp-2017-316633 pmid:28889093

    Abstract/FREE Full Text
15. 15.↵
    2. Hobbs NZ,
    3. Barnes J,
    4. Frost C, et al

    . Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036–41 doi:10.3174/ajnr.A2018 pmid:20150305

    Abstract/FREE Full Text
16. 16.↵
    2. Aylward EH,
    3. Rosenblatt A,
    4. Field K, et al

    . Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003;62:137–41 doi:10.1016/j.brainresbull.2003.09.005 pmid:14638387

    CrossRefPubMed
17. 17.↵
    2. Gregory S,
    3. Scahill RI,
    4. Seunarine KK, et al

    . Neuropsychiatry and white matter microstructure in Huntington's disease. J Huntingtons Dis 2015;4:239–49 doi:10.3233/JHD-150160 pmid:26443926

    CrossRefPubMed
18. 18.↵
    2. Wolf RC,
    3. Sambataro F,
    4. Vasic N, et al

    . Default-mode network changes in preclinical Huntington's disease. Exp Neurol 2012;237:191–98 doi:10.1016/j.expneurol.2012.06.014 pmid:22742947

    CrossRefPubMed
19. 19.↵
    2. Klöppel S,
    3. Stonnington CM,
    4. Petrovic P, et al

    . Irritability in pre-clinical Huntington's disease. Neuropsychologia 2010;48:549–57 doi:10.1016/j.neuropsychologia.2009.10.016 pmid:19878688

    CrossRefPubMed
20. 20.↵
    2. Montal V,
    3. Vilaplana E,
    4. Alcolea D, et al

    . Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimers Dement 2018;14:340–51 doi:10.1016/j.jalz.2017.09.013 pmid:29080407

    CrossRefPubMed
21. 21.↵
    2. Gispert JD,
    3. Suárez-Calvet M,
    4. Monté GC, et al

    . Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimers Dement 2016;12:1259–72 doi:10.1016/j.jalz.2016.06.005 pmid:27423963

    CrossRefPubMed
22. 22.↵
    2. Simmons DA,
    3. James ML,
    4. Belichenko NP, et al

    . TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31. Hum Mol Genet 2018;27:2893–912 doi:10.1093/hmg/ddy202 pmid:29860333

    CrossRefPubMed